Yes more fiction writing. The reality is that the stock is unbelievably in the $1.70's and the "newbie" list is getting shorter as the supposed catalyst's for moving the stock are getting smaller. Lets see we now have to check off the CA lawsuit and the start to the Yervoy trial. It looks painfully obvious that the only thing that will move this stock is a partner, buyout or a real financing deal. I know we should all be thankful that PPHM walked away from the ABBIE deal. Reality is that we were above 5 on the rumour and financing deal and we are at $1.71 now. Doesn't look or feel like shareholders are better off. All imo.
The fact that COTARA is in phase III is an accomplishment IMO. It means the drug is good enough to be there. You cannot expect a small company to spend a money they dont have doing in all sorts of trials. You have to choose just the most efficient ones and stick to them. COTARA can wait, patients I am afraid they cant but that is another story where politicians should do something about
News 
Market Data 
Discover 
AI
